Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC

Journal of Thoracic Oncology 2026 Open access

Read full text
Authors: Daan A. C. Lanser, Lisanne N. van Merendonk, G. D. Marijn Veerman, Salomé van Beusekom, Esther Oomen‐de Hoop, Peter De Bruijn, Attila Icli, Marthe S. Paats, Alwin D. R. Huitema, Ron H.N. van Schaik, Sushil K. Badrising, Anne‐Marie C. Dingemans
+1 more Ron H.J. Mathijssen
DOI: 10.1016/j.jtho.2026.104093
Cited by: 1
References: 8

Abstract

above the toxicity threshold, representing approximately one-third of patients, might prevent severe toxicity and improve treatment tolerability.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Lung Cancer Research Studies

Publication details

Journal / source
Journal of Thoracic Oncology
Publisher
Elsevier BV
Pages
104093–104093
Publication date
1 July 2026
Language
EN